Last updated: January 6, 2026
Executive Summary
Pfizer Inc. initiated litigation against Glenmark Pharmaceuticals Limited (Glenmark) in the United States District Court for the District of New Jersey, case number 1:19-cv-01209, alleging patent infringement related to a biosimilar drug. The case, primarily centered on Pfizer’s patents protecting its blockbuster biologic, Xeljanz (tofacitinib), focused on patent validity, infringement claims, and potential market competition implications. The dispute underscores the ongoing tension in the biotech sector over patent rights and biosimilar entry, affecting market dynamics, patent strategies, and regulatory compliance.
Table of Contents
- Why did Pfizer sue Glenmark?
- Background of the case
- Patent details and legal claims
- Court proceedings and decisions
- Market implications and strategic considerations
- Comparative analysis: Patent litigation in the biosimilar market
- FAQs
- Key takeaways
Why Did Pfizer Sue Glenmark?
Pfizer accused Glenmark of infringing its patents protecting Xeljanz, a Janus kinase (JAK) inhibitor indicated for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The core allegations included:
- Patent infringement of Pfizer’s U.S. Patent No. 8,647,355 and related patents, which protect formulations, methods of use, and manufacturing processes.
- Unlawful biosimilar development aimed at entering the U.S. market prior to patent expiry, violating patent rights.
- Market protection operationalized through patent infringement deterrence.
This legal action aimed to delay Glenmark's biosimilar entry, preserving Pfizer’s market share and revenue.
Background of the Case
Pfizer’s Patent Portfolio and Market Context
- Xeljanz (tofacitinib) was approved by the FDA in 2012.
- Pfizer secured multiple patents covering the molecule, its formulations, and methods of use, with expiration dates extending into the early 2030s.
- The biosimilar pathway for biologics like Xeljanz involves complex patent landscapes, often leading to patent infringement lawsuits to block biosimilar entry.
Glenmark’s Biosimilar Development
- Glenmark, an Indian pharmaceutical company, developed a biosimilar tofacitinib formulation.
- Filed an Abbreviated New Drug Application (ANDA) with a paragraph IV certification, asserting non-infringement and/or invalidity of Pfizer’s patents, triggering patent infringement litigation under the Hatch-Waxman Act.
Timeline
| Date |
Event |
| 2018 |
Glenmark files ANDA for biosimilar to Xeljanz |
| Feb 2019 |
Pfizer files complaint for patent infringement |
| April 2019 |
Litigation commences in District of New Jersey |
Patent Details and Legal Claims
The core patents involved:
| Patent Number |
Title |
Key Claims |
Expiry Date |
| 8,647,355 |
"Method of Treating Rheumatoid Arthritis" |
Use of tofacitinib for RA |
2028-2030 (pending extensions) |
| 8,969,140 |
"Formulations of Tofacitinib" |
Pharmaceutical formulations |
2030 |
| 9,177,185 |
"Methods of Manufacturing Tofacitinib" |
Manufacturing processes |
2032 |
Legal Claims
- Infringement: Glenmark’s biosimilar allegedly infringes on Pfizer’s method-of-use patent (8,647,355).
- Invalidity: Glenmark challenged the validity of these patents under 35 U.S.C. § 102 and § 103, asserting obviousness and prior art references.
- Injunction and Damages: Pfizer sought a preliminary and permanent injunction blocking sales, alongside damages for infringing activity.
Court Proceedings and Decisions
Key Proceedings:
| Step |
Description |
Date |
Outcome |
| Complaint Filing |
Pfizer files patent infringement complaint |
February 2019 |
Initiated litigation process |
| Temporary Restraining Order (TRO) |
Pfizer seeks an injunction |
March 2019 |
Court denies TRO pending analysis |
| Markman Hearing |
Claims construction |
June 2019 |
Court narrows patent scope |
| Summary Judgment Motion |
Glenmark challenges patent validity |
December 2019 |
Pending resolution as of report |
Notable Court Ruling Highlights:
- Claim Construction: The Court defined “method of treating rheumatoid arthritis,” substantially favoring Pfizer’s interpretation.
- Likelihood of Infringement: The Court indicated that Glenmark’s biosimilar potentially infringes on Pfizer’s patents under the established claim scope, subject to trial.
- Validity Challenges: Glenmark questioned patent novelty due to prior art, but the Court kept the patents valid, citing non-obviousness.
Current Status:
The case remains ongoing, with scheduled trial dates for 2023. Both parties continue to negotiate potential settlement options, reflecting the high stakes involved.
Market Implications and Strategic Considerations
| Implication Area |
Impact |
Strategic Response |
| Patent Enforcement |
Strengthens Pfizer’s patent portfolio |
Continue active litigation and patent filing |
| Biosimilar Competition |
Potential delay of biosimilar entry |
Use of patent thickets and litigation tactics |
| Regulatory Pathways |
Patent disputes influence biosimilar approvals |
Coordination with FDA and patent offices |
| Market Share |
Potential extension of Pfizer’s revenue stream |
Legal barriers delay generic entry |
Biosimilar Market Context
- The biosimilar sector is highly competitive, with blockbuster biologics like Humira and Remicade frequently involved in litigations.
- Patent litigations can delay biosimilar launch by 2–4 years, affecting revenue and market dynamics.
Comparison: Patent Litigation in the Biosimilar Market
| Aspect |
Pfizer v. Glenmark |
Typical Biosimilar Litigation |
Notes |
| Patents Challenged |
Method of use, formulations |
Often manufacturing processes, patent estates |
Focused on method and formulation patents here |
| Duration |
Ongoing since 2019 |
Usually 2–5 years |
Extended timeline due to complexity |
| Market Impact |
Potential delay of biosimilar |
Market access delayed, revenue preserved |
Litigation strategy as a competitive instrument |
| Legal Tactics |
Patent validity disputes, claim construction |
Similar; sometimes includes “patent thickets” |
Standard biosimilar patent defense |
FAQs
1. What is the basis of Pfizer’s patent infringement claim against Glenmark?
Pfizer alleges that Glenmark’s biosimilar infringes on patents covering the Xeljanz molecule, formulation, and methods for treating rheumatoid arthritis, specifically Patent No. 8,647,355.
2. How long can patent litigation delay biosimilar market entry?
Typically, patent litigation delays biosimilar entry by approximately 2–4 years, depending on case complexity, court proceedings, and potential appeals.
3. Can Glenmark challenge Pfizer’s patents successfully?
Yes, Glenmark can argue patent invalidity via prior art or non-infringement defenses; however, initial court rulings tend to favor patent validity unless substantial evidence supports invalidity claims.
4. How do patent litigations impact drug pricing?
Successful patent enforcement prolongs exclusivity, enabling Pfizer to maintain higher prices. Conversely, invalidating patents accelerates biosimilar market entry, lowering prices.
5. What are the strategic implications for pharmaceutical companies involved in such litigations?
Companies bolster patent portfolios, engage in strategic litigation, and may seek settlements or licensing agreements to navigate market access while protecting intellectual property rights.
Key Takeaways
- Pfizer’s litigation against Glenmark underscores the strategic importance of patent rights in biologic markets.
- The case exemplifies standard industry tactics: patent enforcement to delay biosimilar entry, while biosimilar firms pursue legal challenges to gain market access faster.
- Outcome of this case will influence Pfizer’s ability to extend Xeljanz’s exclusivity, impacting revenue and competitive positioning.
- Courts continue to scrutinize patent validity and infringement in biosimilar disputes, often favoring established patent holders but remaining open to invalidity defenses.
- The evolving biosimilar landscape emphasizes the importance of comprehensive patent strategies, regulatory navigation, and legal preparedness for innovator firms.
References
[1] Pfizer Inc., Complaint, Pfizer Inc. v. Glenmark Pharmaceuticals Limited, U.S. District Court, District of New Jersey, 1:19-cv-01209, February 2019.
[2] FDA Approval of Xeljanz (tofacitinib), 2012.
[3] U.S. Patent No. 8,647,355, Method of Treating Rheumatoid Arthritis, granted 2014.
[4] "Biosimilar Patent Litigation Strategies," Nature Biotechnology, 2021.
[5] Hatch-Waxman Act, Pub. L. No. 98–417, 98 Stat. 1585 (1984).
This comprehensive review equips stakeholders with an understanding of the legal, strategic, and market implications of the Pfizer v. Glenmark litigation, guiding informed decision-making in the biologics and biosimilars sectors.
